In this Deloitte White Paper, cooperation is described as key to competition for biopharmaceutical companies and the reliance on a traditional, closed R&D model might stifle true innovation. The paper discusses how companies that adopt a cooperative, open innovation framework are likely to spur product development, speed time to market, reduce costs, and increase competitiveness, and ultimately deliver a three-fold increase in the probability of success (achieving marketing approval) when drugs are sourced via open innovation.

Access the full article at https://www2.deloitte.com/us/en/pages/life-sciences-and-health-care/articles/biopharma-open-innovation.html